These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37937640)

  • 21. Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer.
    Yan X; Yao C; Fang C; Han M; Gong C; Hu D; Shen W; Wang L; Li S; Zhu S
    Int J Biol Sci; 2022; 18(2):585-598. PubMed ID: 35002511
    [No Abstract]   [Full Text] [Related]  

  • 22. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
    Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
    Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
    Wu C; Fan M; Hu Y
    Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
    Rathkey D; Khanal M; Murai J; Zhang J; Sengupta M; Jiang Q; Morrow B; Evans CN; Chari R; Fetsch P; Chung HJ; Xi L; Roth M; Filie A; Raffeld M; Thomas A; Pommier Y; Hassan R
    J Thorac Oncol; 2020 May; 15(5):843-859. PubMed ID: 32004714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
    Gong X; Du J; Parsons SH; Merzoug FF; Webster Y; Iversen PW; Chio LC; Van Horn RD; Lin X; Blosser W; Han B; Jin S; Yao S; Bian H; Ficklin C; Fan L; Kapoor A; Antonysamy S; Mc Nulty AM; Froning K; Manglicmot D; Pustilnik A; Weichert K; Wasserman SR; Dowless M; Marugán C; Baquero C; Lallena MJ; Eastman SW; Hui YH; Dieter MZ; Doman T; Chu S; Qian HR; Ye XS; Barda DA; Plowman GD; Reinhard C; Campbell RM; Henry JR; Buchanan SG
    Cancer Discov; 2019 Feb; 9(2):248-263. PubMed ID: 30373917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entanglement of Methylation Changes and cGAS-STING Signaling in Non-Small-Cell Lung Cancer.
    Hao F
    Comb Chem High Throughput Screen; 2023; 26(1):224-235. PubMed ID: 35585823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP Inhibitors in Ovarian Cancer.
    Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
    Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
    Gamba T; Paparo J; Panepinto O; Dionisio R; Di Maio M; Vignani F
    Clin Genitourin Cancer; 2023 Oct; 21(5):509-516. PubMed ID: 37500375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 31. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
    Ferrarotto R; Cardnell R; Su S; Diao L; Eterovic AK; Prieto V; Morrisson WH; Wang J; Kies MS; Glisson BS; Byers LA; Bell D
    Head Neck; 2018 Aug; 40(8):1676-1684. PubMed ID: 29570891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells.
    Bulanova D; Akimov Y; Senkowski W; Oikkonen J; Gall-Mas L; Timonen S; Elmadani M; Hynninen J; Hautaniemi S; Aittokallio T; Wennerberg K
    Sci Adv; 2024 May; 10(21):eadj1564. PubMed ID: 38781347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
    Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
    BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer.
    Gao Y; Zhang N; Zeng Z; Wu Q; Jiang X; Li S; Sun W; Zhang J; Li Y; Li J; He F; Huang Z; Zhang J; Gong Y; Xie C
    Clin Transl Med; 2022 Apr; 12(4):e792. PubMed ID: 35415876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics.
    Lyu J; Yang EJ; Zhang B; Wu C; Pardeshi L; Shi C; Mou PK; Liu Y; Tan K; Shim JS
    Nat Commun; 2020 Oct; 11(1):5105. PubMed ID: 33037191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
    Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
    Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SAMHD1 silencing cooperates with radiotherapy to enhance anti-tumor immunity through IFI16-STING pathway in lung adenocarcinoma.
    Li Y; Gao Y; Jiang X; Cheng Y; Zhang J; Xu L; Liu X; Huang Z; Xie C; Gong Y
    J Transl Med; 2022 Dec; 20(1):628. PubMed ID: 36578072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.
    Liu P; Lin C; Liu L; Lu Z; Tu Z; Liu H
    J Biol Chem; 2022 Sep; 298(9):102354. PubMed ID: 35952757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
    Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
    Marcoux N; Gettinger SN; O'Kane G; Arbour KC; Neal JW; Husain H; Evans TL; Brahmer JR; Muzikansky A; Bonomi PD; Del Prete S; Wurtz A; Farago AF; Dias-Santagata D; Mino-Kenudson M; Reckamp KL; Yu HA; Wakelee HA; Shepherd FA; Piotrowska Z; Sequist LV
    J Clin Oncol; 2019 Feb; 37(4):278-285. PubMed ID: 30550363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.